Growth Opportunities in Global Biotech Investment, 2024

Description

Big Biopharma Companies Disruptive Technologies and Portfolio Realignment Will Ensure the Growth Potential of Biotech Investments

In this analysis, Frost & Sullivan provides critical insights into the biotech M&A and venture capital (VC) investment, highlighting the drivers, challenges, predictions, and major trends in the biotech segment. This analysis also identifies actionable growth opportunities for industry participants to leverage.

To understand the trend outlook for 2024 and beyond, this analysis assesses strategic and financial investments, mergers and acquisitions (M&A), VC investments, and private equity (PE) from 2019 to 2023. Frost & Sullivan has gathered the total numbers for the entire ecosystem. However, the analytics only include the biotech/biopharma deals not involving small-molecule assets. The scope of this analysis is global, with 2023 as its base year, and includes forecasts up to 2028.

This assessment does not include debt deals and open deals. The deal volumes and values can vary because the data comes from secondary sources. Similarly, definitions for biotech vary. While certain sources record an M&A deal on the announcement date, some record the milestones as the transaction goes through, and others record the total value after completing the transaction.

Product Code: PFGA-52

Transformation in Global Biotech Investment

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on Global Biotech Investments

Ecosystem

Market Scope and Segmentation
Definitions

Growth Generator

Growth Drivers
Growth Restraints
The State of the Biotech Industry-Biologics Pipeline
State of the Biotech Industry-Biologics Industry Outlook
Biotech M&A Investment Outlook-2024
Biotech VC Investment Outlook-2024
Top 3 Predictions-2024
Top 3 Big Pharma Investment Strategies for Portfolio Remodeling
Emerging Biotech Companies Top Trends-Impact Summary
New Modalities Driving Precision Medicine Will Remain Attractive
Investors Prioritizing Cardiometabolism, Oncology, CNS, and Immunology

Growth Generator: Biotech M&A

Biotech M&A Trends
Big Biopharma M&A Activity
Biotech M&A Analysis by Therapeutic Segment
Biotech M&A Analysis by Modality
Key Biopharma M&A Targets2024

Growth Generator: Biotech VC Investment

Biotech VC Financing Trend
Top VC Financing Deals
Biotech VC Deal Analysis by Funding Stage
Biotech VC Deal Analysis by Therapeutic Segment
Biotech VC Deal Analysis by Modality
Biotech VC Deal Analysis by Stage of Clinical Development

Companies to Action

Google Ventures (United States)
ARCH Ventures (United States)
RA Capital (United States)
SamsaraBio Capital (United States)
OrbiMed (United States)
Alexandria (United States)

Growth Opportunity Universe

Growth Opportunity 1: Acquiring Rare Disease-focused Biopharma Companies
Growth Opportunity 2: Investing in Precision Medicine Platform Technology-based Biotech Companies
Growth Opportunity 3: Investing in Clinical-stage Chinese Biopharma Companies

Best Practices Recognition

Best Practices Recognition

Frost Radar

Frost Radar

Next Steps

Benefits and Impacts of Growth Opportunities
Next Steps
Take the Next Step
List of Exhibits
Legal Disclaimer